Giant Congenital Melanocytic Nevus Report From 30 Years of Experience in a Single Department
Giant Congenital Melanocytic Nevus Report From 30 Years of Experience in a Single Department
复制标题
DOI：
10.1097/sap.0b013e3182920c3d
复制
发表时间：
2015-02-01
影响因子：
1.5
通讯作者：
Schmidt, Grethe
中科院分区：
文献类型：
--
作者：
Rasmussen, Bo Sonnich;Henriksen, Trine Foged;Schmidt, Grethe
巨大先天性黑素细胞痣（GCMN）发生率为1:20 000，与恶性转化的风险增加有关。回顾了1981年至2010年在三级转诊中心对GCMN的治疗，评估了使用的方式、美容效果、相关并发症和恶性转化。在35名患者中，25人接受了手术。刮除最常用（64%），其次是切除和组织扩张（20%）。6%接受刮除治疗的患者和78%接受切除手术的患者分别需要1次以上的计划手术，25%和44%需要计划外的额外手术。分别有25%和67%的患者出现并发症。76%的患者美容效果满意，两组间无差异。在平均11年的随访中未发现恶性转化。刮除术是一种温和的替代手术，并发症发生率低，美容效果好。
Giant congenital melanocytic nevi (GCMN) occur in 1:20,000 livebirths and are associated with increased risk of malignant transformation. The treatment of GCMN from 1981 to 2010 in a tertiary referral center was reviewed evaluating the modalities used, cosmetic results, associated complications, and malignant transformation. Of 35 patients, 25 underwent surgery. Curettage was most frequently used (64%) followed by excision and tissue expansion (20%). Six percent of the patients treated with curettage, and 78% of the patients who received excision surgery required more than 1 planned procedure, and 25% versus 44% required unplanned additional surgery, respectively. Complications were noted in 25% and 67% of the patients, respectively. Cosmetic result was satisfying in 76% of patients without difference between the groups. No malignant transformation was found during a mean follow-up of 11 years. Curettage is a gentle alternative to excision with a lower complication rate and good cosmetic outcome.